Previous 10 | Next 10 |
2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...
Neurocrine Biosciences to Host Analyst Day on December 5, 2023 PR Newswire SAN DIEGO , Dec. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&a...
2023-11-30 12:16:34 ET Summary Neurocrine Biosciences' stock has been stagnant due to a lack of appreciation for positive updates and the modest mid-stage pipeline setbacks. The company recently settled with generic filers, ensuring no generic launch of Ingrezza until 2038 and hig...
2023-11-30 09:53:30 ET More on Neurocrine Biosciences Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success Neurocrine settles all patent disputes related to movement disorder therapy Neurocrine reports Phase 2 study failures for two...
2023-11-13 13:23:47 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PR Newswire SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,...
2023-11-09 16:56:54 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...
Neurocrine Biosciences Provides Development Pipeline Update PR Newswire Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-106584...
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia PR Newswire SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)...
Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference PR Newswire SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Announces CEO Succession Plan PR Newswire Board of Directors appoints Kyle Gano , Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman , Ph.D., to continue to serve on the ...
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 PR Newswire New CAHtalyst™ Pediatric and CAHtalyst!...
2024-05-28 07:00:15 ET Ashwani Verma from UBS issued a price target of $193.00 for NBIX on 2024-05-28 05:23:00. The adjusted price target was set to $193.00. At the time of the announcement, NBIX was trading at $139.4. The overall price target consensus is at $136.41 wit...